Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 7,100 shares, a decrease of 12.3% from the July 31st total of 8,100 shares. Based on an average trading volume of 19,100 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Indaptus Therapeutics in a report on Monday, June 17th.

Indaptus Therapeutics Stock Down 0.8 %

NASDAQ INDP traded down $0.01 during trading on Monday, hitting $1.65. 2,700 shares of the stock traded hands, compared to its average volume of 42,812. The company has a market capitalization of $14.07 million, a P/E ratio of -0.93 and a beta of 1.39. Indaptus Therapeutics has a 12-month low of $1.56 and a 12-month high of $4.08. The firm has a 50-day simple moving average of $1.95 and a 200-day simple moving average of $2.15.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Monday, August 12th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. As a group, research analysts predict that Indaptus Therapeutics will post -1.72 EPS for the current fiscal year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.